Objective: To present an entirely new theory and practical solution to completely eliminate HIV-1 from the human body, based on a combination between a HAART regimen
INTRODUCTION
Time has come for Science and Medicine to win the battle against HIV and AIDS. Since a classical vaccine against HIV-1 is hard to design or even define, and since current HAART (highly-active-anti-retroviral-therapy) and even Mega-HAART regimens are unable to clear an HIV-1 infection, a combined strategy has to be adopted, in order to achieve HIV-1 eradication.
This article presents an entirely new theory and practical solution to eradicate HIV-1 (from the body of HIV-1 infected persons), based on HIV-1's ability and need to mutate under HAART (or Mega-HAART) pressure, and on the synergetical scissoring effect on HIV-1 of successive (Vaccine-x,HAART-x)-couples, which are each formed of:
1. a therapeutic-vaccine (Vaccine-x) consisting of short DNA-sequences of HIV-1 which contain (or bear in their biochemical structure) the point-mutations (PM), (resistance-mutations-pattern , RMP-x) that would be induced into HIV-1's genomic blueprint (biochemical structure) by the following, to come, HAART-x regimen; and of 2. the corresponding, following, (HAART-x) regimen itself.
DESIGN AND METHODS
HIV-1 recombination and mutation ( 1 , 2 , 3 , 4 , 5 , 6 ), including "resistance-mutation", are important mechanisms by which HIV-1 evades drug or immune pressures.
HIV-1-strains that are resistant to an antiretroviral drug present multiple " point-mutations" (PM), which act in synergy to confer the resistant phenotype to that drug, and we may define these "point-mutations" as resistancemutations-loci (RML) or resistance-mutations-sites (RMS), whereas their ensemble may be termed as resistancemutations-pattern (RMP).
Multidrug resistant HIV-1 strains arise in patients treated with HAART or Mega-HAART regimens, either through direct mutation or through recombination of variants that are resistant to single drugs.
Paradoxically, and luckily at the same time, point-mutations (PM) that confer drug -resistance, and consequently the whole resistance-mutations-pattern (RMP-x) of a (HAARTx) regimen offers us the complete biochemical information, for the development of very specific and powerfull vaccine(s) and therapeutic vaccines (Vaccine-x) against HIV-1.
The drug-induced point-mutations (PM) on HIV-1's genome, i.e. the resistance-mutations-loci (RML) or resistancemutations-sites (RMS), and even the whole resistancemutations-pattern (RMP) of any particular (HAART-x) regimen may be introduced, (in form of short HIV-1-DNAsequences which contain the point-mutations) in a multivalent, polivalent or multivalent-polivalent-therapeuticvaccine (Vaccine-x) aimed to prevent the emergence of (HAART-x) -resistant HIV-1 virus.
If (Vaccine-x) is now preadministrated to (HAART-x), the emergence of (HAART-x) -resistant HIV-1 virus is prevented, and thus (HAART-x) will eradicate HIV-1 from the blood and body of infected individuals.
In HIV-1 infection, the infected hosts apparently cannot solve the problem of identifying an antigen that is conserved among the variants and quasispecies, and thereby neutralize the infection. Paradoxically and luckily again, both HAART and/or Mega-HAART regimens are not only reducing HIV-1 viral loads to 50 copies/ml or less, but they are also "UNIFYING" HIV-1's genetic diversity, by "artificially" creating a "common factor" among the remaining/surviving (50-400) copies/ml of HAART-resistant-HIV-1, in form of these point-mutations (PM), ( i.e. resistance-mutations-loci, resistance-mutations-sites ), which together build the resistance-mutations-pattern (RMP).
The list below presents the point-mutations induced by a particular antiretroviral drug, (or by a combination of antiretroviral drugs), into HIV-1's genomic blueprint. An excellent review about HIV-1 therapeutic vaccines ( 7 ) and an article about the role of therapeutic vaccines in the control of HIV-1 in the HAART era ( 8 ) have been published by Kinloch-de Loes and Autran ( 7 , 8 ).
With the availability of HAART, an unique opportunity arises and exists, to enhance anti-HIV immunity by adding anti-HIV-1 therapeutic vaccines as an additional therapeutic option for HIV-infected patients, which will proove to be critical to the conversion of HIV/AIDS to a manageable long-term infection, and ultimately to HIV/AIDS eradication. HAART offers new opportunities for the design of new therapeutic immunisation strategies. An anti-HIV-1 therapeutic vaccine is meant to treat existing HIV-1 infections. More of a treatment than a vaccine in the classic sense of the word, a therapeutic vaccine against HIV-1 is meant to teach the immune system to fight the existing infection. In theory, a therapeutic vaccine should reduce the severity of an infection that already exists, and in a bestcase-scenario, it should direct the immune system to the point where the infection is completely controlled and finally eliminated.
Using an "ad conventium" terminology, a multivalent therapeutic vaccine (MTV-x) against HIV-1, should be designed to elicit an immune response to several different antigenic determinants of a single pathogenic agent or a single strain (e.g. a single strain of HIV-1). In multivalent vaccines, the optimal association or combination of antigens must be assessed to obtain synergistic effects. For example, a multivalent therapeutic vaccine made of short HIV-1 sequences which contain the resistance-mutations A62V, V75I, F77L, F116Y and Q151M should be pre-administrated to the triple drug combination AZT + ddI/ddC in order to achieve the best results in terms of viral reduction.When the drug combination (AZT + 3TC) is used as the drug component of the (Vaccine-x , HAART-x)-couple, it should be preceded by a multivalent therapeutic vaccine (Vaccinex) made of short HIV-1 sequences which contain the resistance-mutations M184V + R211K + L214F / G333D, G333E in order to achieve a powerful synergetical effect in HIV-1 viral reduction. As can be seen, we have chosen the drug-resistance-point-mutations of HIV-1 as antigenic determinants, to be used in therapeutic vaccines against HIV-1, and these therapeutic vaccines against HIV-1 (Vaccine-x), prevent the emergence of HAART-x resistant HIV-1, when pre-administrated to (HAART-x) -which eliminates the HAART-x sensitive HIV-1. In this way (Vaccine-x , HAART-x) -couples can efficiently fight HIV-1 and eliminate it.
Each drug-induced-point-mutation, or each HAART-xinduced-point-mutation (PM), taken separately, can be used as a simple therapeutic-vaccine (STV-x) against HIV-1. Simple therapeutic vaccines (STV-x) against HIV-1, may also be used in couples with both single antiretroviral drugs, or with multiple drugs, or with HAART-x regimens. For example, a simple therapeutic vaccine (STV-x) based on point-mutation M41L can be used together with AZT (Retrovir®) monotherapy in a simple couple termed as ( Vaccine-M41L, AZT (Retrovir®) ). Another simple therapeutic vaccine (STV-x) based only on point-mutation A62V can be used e.g. together with 3 drugs (AZT + ddI/ddC) in a couple termed as (Vaccine-A62V , AZT + ddI/ddC). Of course, a multivalent therapeutic vaccine (MTV-x) based on an entire resistance-mutations-pattern (RMP) like (Vaccine -A62V, V75I, F77L, F116Y, Q151M) and used in a couple termed as (Vaccine -A62V, V75I, F77L, F116Y, Q151M , AZT + ddI/ddC) would be probably more efficient against HIV-1 than the couple (Vaccine-A62V , AZT + ddI/ddC), which is based on a simple therapeutic vaccine only, namely Vaccine-A62V.
A polyvalent therapeutic vaccine (PTV-x) against HIV-1 would be one prepared from antigens, of at least two different strains of HIV-1 and it should be able to efficiently prevent the emergence of at least two different HIV-1 strains. The antigens of such a polyvalent therapeutic vaccine (PTV-x) against HIV-1 would consist of short DNAsequences which include the point-mutations of at least two different HIV-1 strains. A polyvalent therapeutic vaccine (PTV-x) should have the capacity to prevent the emergence of at least 2 resistance-mutations-patterns which would be generated by at least 2 different, successive HAART-x (or Mega-HAART -x) regimens, or it should be able to prevent the emergence of at least two successive resistancemutations-patterns which would be generated by the use of a HAART-x regimen.
A multivalent-polyvalent therapeutic vaccine (MPTV -x) against HIV-1 should be able to prevent the emergence of a very high number of successive resistance-mutationspatterns (RMP-s) which would be generated by a single HAART-x (or Mega-HAART -x) regimen and, ideally, it should be able to eradicate HIV-1 by acting synergetically with all possible successions of HAART-x or Mega-HAART-x regimens, and/or by preventing the emergence of all HIV-1 resistance-mutations-patterns that would be generated by successive HAART-x or Mega-HAART-x regimens, till eradication.
Interestingly and noteworthy, within each ( Vaccine-x , HAART-x)-couple, and by analogy within each (Vaccine-x , Mega-HAART-x)-couple, the (simple, polyvalent, multivalent, or multivalent-polyvalent ) therapeutic vaccine (Vaccine-x) acts in fact like a true vaccine, like a CLASSICAL VACCINE, against the HAART-x-resistant HIV-1 virus (or Mega-HAART-x-resistant HIV-1 virus), by preventing its emergence.
Each antiretroviral drug, and any HAART-x or Mega-HAART-x regimen, divides the HIV-1 viral population in two:
1. drug-sensitive-HIV-1, -which is eliminated by the respective antiretroviral drug , HAART-x , or Mega-HAART-x regimen 2. drug-resistant-HIV-1, -whose emergence can be prevented when the therapeutic vaccine (Vaccine-x) , ( made of short HIV-1 sequences which bear/contain the pointmutations that would be generated by HAART-x or Mega-HAART-x on HIV-1's genome), is pre-administrated to HAART-x (or Mega-HAART-x) respectively.
If a pre -HAART-x administrated therapeutic vaccine (Vaccine-x) manages to prevent the emergence of HAARTx-resistant-HIV-1, then an HIV-1 infection can be cleared and eradicated from the body of an HIV-1 infected patient, since the corresponding , following, to come HAART-xregimen will eliminate the HAART-x-sensitive-HIV-1.
RESULTS
The general HIV-1 eradication scheme is a succession, or series, of (Vaccine-x, HAART-x)-couples: (x is an integer, which takes values from 1 to n) By "corresponding (HAART-x)" regimen we understand the HAART-regimen which would induce into HIV-1s genome a resistance-mutations-pattern (RMP-x) which is prevented from emergence by the pre-administration of the therapeutic vaccine (Vaccine-x).
Of course, if the eradication of HIV-1 from the body of HIV-1-infected patients cannot be achieved by a succesion of (Vaccine-x, HAART-x)-couples, a succesion or series of (Vaccine-x , MegaHAART-x)-couples should be employed in order to eliminate HIV-1.
Two Latin sayings explain the rationale of using (Vaccine-x , HAART-x)-couples or (Vaccine-x , Mega-HAART-x)-couples in the eradication of HIV-1.
"Divide et Impera" perfectly describes the role and action of HAART-x regimens (or Mega-HAART-x regimens), which divide the HIV-1 viral population in HAART-x-sensitivevirus (which is eliminated/cleared by HAART-x) , and HAART-x resistant-virus , whose emergence is prevented by the therapeutic vaccine (Vaccine-x).
Therapeutic vaccine (Vaccine-x) is always pre-administrated to HAART-x according to the main principle of prevention, vaccination and homeopathy "Similia Similibus Curentur" , and in fact, this therapeutic vaccine against HIV-1 (Vaccinex) acts like a classical vaccine within its corresponding (Vaccine-x , HAART-x)-couple.
Infection and immunity are two sides of the same coin.
Therefore it is reasonable and scientifically sound to vaccinate an HIV-1 positive person with a therapeuticvaccine (Vaccine-x) consisting of short DNA-sequences of HIV-1 which contain or bear the individual point-mutations (PM-x), (which together represent the entire resistancemutations-pattern , RMP-x), which would be induced into HIV-1's genomic blueprint (biochemical structure) by the following, to come, HAART-x regimen. should be administrated, (during therapy with HAART-n), consisting of the same short DNA-sequences, but of unmutated, wild-type HIV-1, since it is well known that HAART-x (or Mega-HAART-x)-mutated HIV-1 virus tends to revert back to wild-type HIV-1 when antiretrovital treatment is stopped or temporarily interrupted (structuredtreatment-interruption -STI). This vaccination with short DNA-sequences of wild-type HIV-1 virus should be done shortly before HAART-n or Mega-HAART-n therapy is stopped (or before previously planned structured-treatmentinterruptions), since it is well known that some wild-type HIV-1 may still be hidden in certain organs or tissue reservoirs and since it is also well-known that eventually surviving HAART-resistant-HIV-1 virus tends to revert to wild-type HIV-1 virus, after HAART-treatment is stopped.
The process of HIV-1 eradication may be divided in 3 main steps, by monitoring HIV-1 viral load decreases: STEP 1 would mean a viral load decrease from 60.000 copies/ml or higher, to 50-400 copies/ml; Current HAART and/or Mega-HAART-regimens make STEP1 possible for some years, but are unable to eliminate .an existing HIV-1 infection and thus they are unable to cure AIDS. Even more, HAART and/or Mega-HAART-regimens (even when combined with any presently available therapeutic vaccine (like e.g. Remune), or with any presently available anti HIV-1 classical vaccine -used as a therapeutic vaccine), are unable to keep viral loads low or undetectable for decades or for a lifetime, which would transform an HIV-1 infection into a long-term or lifelong manageable disease.
Our combination of a single (HAART-x) regimen and of its corresponding (multivalent or polivalent) therapeutic vaccine (Vaccine-x) pre-administrated to (HAART-x), which we have termed as a (Vaccine-x , HAART-x)-couple in this article, would probably achieve superior results to any HAART or Mega-HAART regimen combined with any presently available therapeutic vaccines, because the components of the (Vaccine-x , HAART-x)-couple act in an optimal synergy. In conclusion, a single (Vaccine-x , HAART-x)-couple would make STEP1 possible, STEP 2 would mean a viral load decrease by further 3 orders of magnitude, from 50-400 copies/ml to 50-400 copies/litre, by employing two or more successive(Vaccine-x , HAART-x)-couples.
STEP 3 would mean a further viral load decrease from 50-400 copies/litre to zero copies/litre, i.e. eradication of HIV-1, by employing successive series (and even cycles of successive series of (Vaccine-x , HAART-x)-couples in repeated cycles, eventually followed by successive (Vaccine-x , MegaHAART-x)-couples, eventually also in repeated cycles. In order to achieve complete eradication of HIV-1 the complexity of the (Vaccine-x) component of the successive (Vaccine-x , HAART-x)-couples should be gradually increased from a simple therapeutic vaccine (STVx) to a multivalent therapeutic vaccine (MTV-x) and from here to a polyvalent therapeutic vaccine (PTV-x) and finally to a multivalent-polyvalent therapeutic vaccine (MPTV -x).
In order to better illustrate the potential anti-HIV-1 power of a couple formed by a multivalent therapeutic vaccine (MTVx) and its corresponding HAART-x -regimen, it can be estimated that such a couple (MTV-x, HAART-x) would be 1000 times (3 orders of magnitude) more efective in reducing viral load than the respective HAART-x -regimen alone, and this estimate is based on the synergy, complementarity, optimization and perfect coordination between the two components of the (Vaccine-x, HAART-x)-couple. A single antiretroviral drug like AZT (Retrovir®) , would become as effective as 3-4 antiretroviral drugs ( i.e. as effective as a HAART-regimen ) in reducing HIV-1 viral load, provided that it is preceded by a multivalenttherapeutic-vaccine (MTV-x) consisting of short DNAsequences of HIV-1 which contain (or bear in their biochemical structure) the point-mutations (PM) which would be induced into HIV-1's genomic blueprint (biochemical structure) by AZT (Retrovir®) , namely M41L, T215Y, T215H / D67N, K70R, K219Q, K219E. We may write the (Vaccine-x , Drug-x) -couple for AZT (Retrovir®) as (Vaccine-M41L, T215Y, T215H / D67N, K70R, K219Q, K219E , AZT-Retrovir® ).
Affymetrix ( http://www.affymetrix.com/index.affx ), a world-leading US company in DNA-chip technology, has developed GeneChip oligonucleotide probe arrays that are manufactured using a high resolution photolitographic fabrication process adapted from the semiconductor industry, for HIV-1 mutations determinations. (A database of companies which are active in the biochips industry can also be found at http://www.biochipnet.com/companies). Affymetrix GeneChip oligonucleotide probe arrays can be used for the very precise identification and determination of drug-induced HIV-1 mutations, and for the development of vaccines and therapeutic vaccines (Vaccine-x) against HIV-1, to be used in (Vaccine-x , HAART-x) -couples.
At this point the legitimate question arises about how short the DNA-sequences of HIV-1, (which contain/bear in their biochemical structure the point-mutations (PM), that would be induced into HIV-1's genomic blueprint by the following, to come, HAART-x regimen), should be or can be, so that
